Type 1 RTA (distal) is failure of alpha-intercalated cells in the collecting duct to secrete H+, causing inability to acidify urine. Positive urine pH with normal anion-gap hyperchloremic acidosis results; chronic acidosis and hypercalciuria predispose to nephrolithiasis and hypokalemia.
From your prerequisites, you know the kidney's central role in acid-base homeostasis: the proximal tubule reabsorbs bicarbonate, and the distal nephron — specifically the alpha-intercalated cells of the collecting duct — secretes free H+ ions into the tubular lumen, acidifying the urine. This distal acidification is the body's primary mechanism for excreting the fixed acid load generated by metabolism (roughly 1 mEq/kg/day). You also know from acid-base definitions that metabolic acidosis is characterized by low pH, low bicarbonate, and compensatory hyperventilation. Type 1 RTA is what happens when that final acidification step fails.
In distal RTA, the alpha-intercalated cells cannot maintain the hydrogen ion gradient between blood and tubular fluid. Normally these cells achieve a urine pH as low as 4.5 — a nearly 800-fold concentration gradient against blood pH 7.4. Failure can stem from defects in the H+-ATPase pump itself (genetic causes, Sjögren's syndrome, autoimmune disease) or from protons "back-leaking" through a damaged collecting duct epithelium (as in amphotericin B toxicity). The result: urine pH cannot fall below 5.3 even in the presence of severe systemic acidosis. This paradox — acidemic blood yet alkaline urine — is the diagnostic hallmark.
The systemic consequences follow logically. Acid accumulation produces hyperchloremic, normal anion-gap metabolic acidosis. Why hyperchloremic? Bicarbonate is consumed buffering excess H+, and chloride replaces it to maintain electroneutrality — the anion gap (Na - Cl - HCO3) stays normal because no unmeasured anion has accumulated. Chronic acidosis mobilizes bone carbonate and phosphate as a secondary buffer, releasing calcium into the circulation and producing hypercalciuria. Combined with alkaline urine (less soluble for calcium phosphate), this drives nephrolithiasis — characteristically calcium phosphate stones. Hypokalemia develops because the collecting duct compensates for impaired H+ secretion by increasing K+ secretion; protons and potassium compete for secretion, and without H+ competing, potassium losses rise disproportionately.
Treatment is mechanistically direct: replace the alkali the kidney cannot regenerate. Oral bicarbonate or citrate salts neutralize the daily acid load, correct systemic acidosis, reduce hypercalciuria, and prevent stone formation. Potassium citrate simultaneously provides alkali and repletes potassium — a single agent that aligns with both the acid and the electrolyte defect. This is a case where understanding the mechanism at the cellular level maps cleanly onto a therapeutic decision.
No topics depend on this one yet.